149 related articles for article (PubMed ID: 12239171)
1. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype.
Li Y; Nagai H; Ohno T; Yuge M; Hatano S; Ito E; Mori N; Saito H; Kinoshita T
Blood; 2002 Oct; 100(7):2572-7. PubMed ID: 12239171
[TBL] [Abstract][Full Text] [Related]
2. Methylation of p16(INK4A) and p57(KIP2) are involved in the development and progression of gastric MALT lymphomas.
Min KO; Seo EJ; Kwon HJ; Lee EJ; Kim WI; Kang CS; Kim KM
Mod Pathol; 2006 Jan; 19(1):141-8. PubMed ID: 16357845
[TBL] [Abstract][Full Text] [Related]
3. The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer.
Zohny SF; Baothman OA; El-Shinawi M; Al-Malki AL; Zamzami MA; Choudhry H
Cancer Biomark; 2017; 18(4):413-423. PubMed ID: 28106536
[TBL] [Abstract][Full Text] [Related]
4. Age-dependent changes of p57(Kip2) and p21(Cip1/Waf1) expression in skeletal muscle and lung of mice.
Park CW; Chung JH
Biochim Biophys Acta; 2001 Aug; 1520(2):163-8. PubMed ID: 11513958
[TBL] [Abstract][Full Text] [Related]
5. Regulation of p57(KIP2) during muscle differentiation: role of Egr1, Sp1 and DNA hypomethylation.
Figliola R; Busanello A; Vaccarello G; Maione R
J Mol Biol; 2008 Jul; 380(2):265-77. PubMed ID: 18513743
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer.
Pateras IS; Apostolopoulou K; Koutsami M; Evangelou K; Tsantoulis P; Liloglou T; Nikolaidis G; Sigala F; Kittas C; Field JK; Kotsinas A; Gorgoulis VG
Int J Cancer; 2006 Dec; 119(11):2546-56. PubMed ID: 16988944
[TBL] [Abstract][Full Text] [Related]
7. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.
Hartmann W; Waha A; Koch A; Goodyer CG; Albrecht S; von Schweinitz D; Pietsch T
Am J Pathol; 2000 Oct; 157(4):1393-403. PubMed ID: 11021841
[TBL] [Abstract][Full Text] [Related]
8. The hallmarks of CDKN1C (p57, KIP2) in cancer.
Kavanagh E; Joseph B
Biochim Biophys Acta; 2011 Aug; 1816(1):50-6. PubMed ID: 21447370
[TBL] [Abstract][Full Text] [Related]
9. Distant cis-elements regulate imprinted expression of the mouse p57( Kip2) (Cdkn1c) gene: implications for the human disorder, Beckwith--Wiedemann syndrome.
John RM; Ainscough JF; Barton SC; Surani MA
Hum Mol Genet; 2001 Jul; 10(15):1601-9. PubMed ID: 11468278
[TBL] [Abstract][Full Text] [Related]
10. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells.
Shin JY; Kim HS; Park J; Park JB; Lee JY
Cancer Res; 2000 Jan; 60(2):262-5. PubMed ID: 10667572
[TBL] [Abstract][Full Text] [Related]
11. Identification of multiple cell cycle regulatory functions of p57Kip2 in human T lymphocytes.
Li G; Domenico J; Lucas JJ; Gelfand EW
J Immunol; 2004 Aug; 173(4):2383-91. PubMed ID: 15294951
[TBL] [Abstract][Full Text] [Related]
12. Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour.
Taniguchi T; Okamoto K; Reeve AE
Oncogene; 1997 Mar; 14(10):1201-6. PubMed ID: 9121769
[TBL] [Abstract][Full Text] [Related]
13. Assessment of p57(KIP2) gene mutation in Beckwith-Wiedemann syndrome.
Gaston V; Le Bouc Y; Soupre V; Vazquez MP; Gicquel C
Horm Res; 2000; 54(1):1-5. PubMed ID: 11182628
[TBL] [Abstract][Full Text] [Related]
14. The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.
Coley HM; Safuwan NA; Chivers P; Papacharalbous E; Giannopoulos T; Butler-Manuel S; Madhuri K; Lovell DP; Crook T
Br J Cancer; 2012 Jan; 106(3):482-9. PubMed ID: 22233925
[TBL] [Abstract][Full Text] [Related]
15. Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia.
Rossi D; Capello D; Gloghini A; Franceschetti S; Paulli M; Bhatia K; Saglio G; Vitolo U; Pileri SA; Esteller M; Carbone A; Gaidano G
Haematologica; 2004 Feb; 89(2):154-64. PubMed ID: 15003890
[TBL] [Abstract][Full Text] [Related]
16. Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer.
Liang B; Wang S; Yang X; Ye Y; Yu Y; Cui Z
Chin Med J (Engl); 2003 Jan; 116(1):20-3. PubMed ID: 12667381
[TBL] [Abstract][Full Text] [Related]
17. Domain regulation of imprinting cluster in Kip2/Lit1 subdomain on mouse chromosome 7F4/F5: large-scale DNA methylation analysis reveals that DMR-Lit1 is a putative imprinting control region.
Yatsuki H; Joh K; Higashimoto K; Soejima H; Arai Y; Wang Y; Hatada I; Obata Y; Morisaki H; Zhang Z; Nakagawachi T; Satoh Y; Mukai T
Genome Res; 2002 Dec; 12(12):1860-70. PubMed ID: 12466290
[TBL] [Abstract][Full Text] [Related]
18. p57(Kip2) regulates the proper development of labyrinthine and spongiotrophoblasts.
Takahashi K; Kobayashi T; Kanayama N
Mol Hum Reprod; 2000 Nov; 6(11):1019-25. PubMed ID: 11044465
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors upregulate p57Kip2 level by enhancing its expression through Sp1 transcription factor.
Cucciolla V; Borriello A; Criscuolo M; Sinisi AA; Bencivenga D; Tramontano A; Scudieri AC; Oliva A; Zappia V; Della Ragione F
Carcinogenesis; 2008 Mar; 29(3):560-7. PubMed ID: 18204075
[TBL] [Abstract][Full Text] [Related]
20. Identification of a functional glucocorticoid response element in the promoter of the cyclin-dependent kinase inhibitor p57Kip2.
Alheim K; Corness J; Samuelsson MK; Bladh LG; Murata T; Nilsson T; Okret S
J Mol Endocrinol; 2003 Jun; 30(3):359-68. PubMed ID: 12790805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
